Essen, Germany – March 4, 2026 – Evonik Industries has released its final financial results for the 2025 fiscal year, confirming preliminary data published in February. The specialty chemicals company met its profit guidance despite persistent market headwinds and reaffirmed its outlook for 2026.

Full Year 2025 Results

Evonik reported full-year sales of €14.1 billion in 2025, a 7% decline from €15.2 billion in the previous year. Adjusted EBITDA reached €1.87 billion, matching the company's forecast of around €1.9 billion, though down 9% from €2.07 billion in 2024. Adjusted EBIT fell 16% to €861 million compared to €1.03 billion in the prior year.

Net income improved to €265 million, up 19% from €222 million in 2024, while adjusted net income decreased 18% to €634 million. The company generated strong free cash flow of €695 million, contributing to a cash conversion rate of 37 percent, reaching the upper end of the target range of 30 to 40 percent.

Fourth Quarter Performance

The fourth quarter of 2025 showed signs of recovery with sales reaching €3.40 billion, a 5% decrease compared to €3.60 billion in Q4 2024 but representing sequential improvement. Adjusted EBITDA for the quarter was €357 million, down 8% year-on-year, while adjusted EBIT declined 5% to €105 million. Notably, the company returned to profitability in Q4 with net income of €18 million, a significant turnaround from the €152 million loss recorded in the same period of 2024.

Dividend and Outlook

Evonik's Executive Board has proposed a dividend of €1.00 per share for the 2025 fiscal year as a transition measure. Starting from fiscal 2026, the annual dividend will be linked to adjusted net income, with between 40 and 60 percent distributed to shareholders. The proposal will be voted on at the Annual General Meeting on June 3, 2026.

For 2026, Evonik reaffirms its outlook for adjusted EBITDA between €1.7 billion and €2.0 billion. In the medium term, the company remains focused on achieving an 11 percent return on capital employed (ROCE), compared to 6.1 percent in 2025.

Source: Evonik